華潤三九(000999.SZ):未來預計各業務線銷售費用率穩中有降
格隆匯6月14日丨華潤三九(000999.SZ)召開電話會議,就“公司銷售費用率下降的原因以及2023年的預期?”
公司回覆稱,公司過去幾年綜合銷售費用率下降主要是業務結構變化影響,CHC業務佔比近年來有所提升,處方藥業務受到集採等政策影響佔比下降。處方藥業務費用率相對較高,因此其下降對於整體費用率有所影響。國藥業務中飲片業務費用率比較低,集採品種的費用率下降,都會導致處方藥業務費用率有所下降。公司對銷售費用管控嚴格,費用投放和業務策略及營收增長相匹配,並不斷加強費用精細化管理。通過費用管控及規模效應產生的費用優化,未來預計各業務線銷售費用率穩中有降。2023年由於昆藥並表的影響,費用率較往年會有變化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.